30 - Lessons Learned in Biopreparedness And Biocontainment: Lassa Fever in the Midwest

Monday, October 20, 2025

10:30 AM - 11:45 AM US ET

Location: B206

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Yohei Doi, MD, PHD (he/him/his)

Professor of Medicine
Division of Infectious Diseases
University of Pittsburgh
Toyoake, Aichi, Japan
Aneesh Mehta, MD (he/him/his)

Professor of Medicine and of Surgery
Department of Medicine
Emory University School of Medicine
Atlanta, GA, United States
AH

Angela Hewlett, MD, MS

Professor, Division of Infectious Diseases
University of Nebraska Medical Center
Omaha, NE, United States

Faculty(s)

Dele Davies, MD, MS, MHCM

Interim Chancellor
University of Nebraska Medical Center
KB

Karen Brust, MD

University of Iowa Hospitals & Clinics
Iowa City, Iowa, United States
Matt Donahue, MD (he/him/his)

State Epidemiologist & Deputy Medical Director
Iowa Department of Health and Human Services
Des Moines, IA, United States
Vicki Herrera, MS

Training & Education Coordinator
Nebraska Biocontainment Unit Laboratory

Disclosure(s):

Yohei Doi, MD, PHD: GSK: Advisor/Consultant; Meiji Seika Pharma: Advisor/Consultant; Shionogi: Advisor/Consultant, Honoraria

Aneesh K. Mehta, MD: No financial relationships to disclose.

Angela Hewlett, MD, MS: Forcast Orthopedics: Advisor/Consultant; Mapp Biopharmaceutical Inc.: Grant/Research Support

Dele Davies, MD, MS, MHCM: No financial relationships to disclose.

Karen Brust, MD: No financial relationships to disclose.

Matt Donahue, MD: No financial relationships to disclose.

Vicki Herrera, MS: No financial relationships to disclose.

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe the clinical presentation and resultant public health response to an identified case of Lassa Fever;
discuss readiness for the clinical and operational care of special populations
explain laboratory processing and specimen management considerations when a special pathogen is suspected or confirmed;
describe the regional and national resources available for the assessment and management of patients with suspected or confirmed special pathogen infections.

Presentations:

10:30 AM - 10:39 AM US ET

Background and Clinical Presentation
Speaker: Karen Brust, MD – University of Iowa Hospitals & Clinics
10:39 AM - 10:48 AM US ET

Epidemiologic Investigation and Public Health Response
Speaker: Matt Donahue, MD (he/him/his) – Iowa Department of Health and Human Services
10:48 AM - 10:57 AM US ET

Regional Emerging Special Pathogen Treatment Center (RESPTC) Support and Response
Speaker: Angela Hewlett, MD, MS – University of Nebraska Medical Center
10:57 AM - 11:06 AM US ET

Special Populations (Pregnant Women, Neonates, Children, Families): Considerations for Quarantine and Biocontainment
Speaker: Dele Davies, MD, MS, MHCM – University of Nebraska Medical Center
11:06 AM - 11:15 AM US ET

Laboratory Response and Considerations
Speaker: Vicki Herrera, MS – Nebraska Biocontainment Unit Laboratory
11:15 AM - 11:45 AM US ET

Panel Discussion and Q&A
Panelist: Karen Brust, MD – University of Iowa Hospitals & Clinics
Panelist: Matt Donahue, MD (he/him/his) – Iowa Department of Health and Human Services
Panelist: Vicki Herrera, MS – Nebraska Biocontainment Unit Laboratory
Panelist: Dele Davies, MD, MS, MHCM – University of Nebraska Medical Center